Direct oral anticoagulants in extremely obese patients: OK to use?
作者信息
Moll Stephan, Crona Daniel J, Martin Karlyn
机构信息
Division of Hematology-Oncology Department of Medicine University of North Carolina School of Medicine Chapel Hill North Carolina.
Division of Pharmacotherapy University of North Carolina Eshelman School of Pharmacy Chapel Hill North Carolina.
出版信息
Res Pract Thromb Haemost. 2018 Dec 24;3(2):152-155. doi: 10.1002/rth2.12178. eCollection 2019 Apr.
Abstract
摘要
相似文献
1
Direct oral anticoagulants in extremely obese patients: OK to use?
Res Pract Thromb Haemost. 2018 Dec 24;3(2):152-155. doi: 10.1002/rth2.12178. eCollection 2019 Apr.
2
Anticoagulation and BMI: effect of high body weight on the safety and efficacy of direct oral anticoagulants.
Future Cardiol. 2022 Sep;18(10):829-837. doi: 10.2217/fca-2021-0146. Epub 2022 Sep 2.
3
Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation.
Cardiovasc Drugs Ther. 2021 Apr;35(2):261-272. doi: 10.1007/s10557-020-07126-2. Epub 2021 Jan 6.
4
Oral Anticoagulant Use in Morbid Obesity and Post Bariatric Surgery: A Review.
Am J Med. 2021 Dec;134(12):1465-1475. doi: 10.1016/j.amjmed.2021.07.017. Epub 2021 Aug 15.
5
A comprehensive multi-institutional study on postoperative adjuvant immunotherapy with oral streptococcal preparation OK-432 for patients after gastric cancer surgery. Kyoto Research Group for Digestive Organ Surgery.
Ann Surg. 1992 Jul;216(1):44-54. doi: 10.1097/00000658-199207000-00007.
6
Use of Direct Oral Anticoagulants in Morbidly Obese Patients.
Pharmacotherapy. 2020 Jan;40(1):72-83. doi: 10.1002/phar.2353. Epub 2019 Dec 30.
7
Safety and efficacy of direct oral anticoagulants across body mass index groups in patients with venous thromboembolism: a retrospective cohort design.
J Thromb Thrombolysis. 2021 Aug;52(2):567-576. doi: 10.1007/s11239-020-02361-8. Epub 2021 Jan 2.
8
Oral direct factor Xa inhibitor gets FDA's OK.
Am J Health Syst Pharm. 2011 Aug 15;68(16):1467. doi: 10.2146/news110054.
9
[Immunity of gut-associated lymphoid tissue and the role of the oral immunotherapy in multi-disciplinary treatment of the digestive organ cancer].
Nihon Geka Gakkai Zasshi. 1989 Sep;90(9):1436-8.
10
Effectiveness of Direct Oral Anticoagulants in Obese Adults With Atrial Fibrillation: A Systematic Review of Systematic Reviews and Meta-Analysis.
Front Cardiovasc Med. 2021 Oct 8;8:732828. doi: 10.3389/fcvm.2021.732828. eCollection 2021.
引用本文的文献
1
Retrospective, multicenter analysis of the safety and effectiveness of direct oral anticoagulants for the treatment of venous thromboembolism in obesity.
J Thromb Thrombolysis. 2024 Apr;57(4):603-612. doi: 10.1007/s11239-024-02955-6. Epub 2024 Feb 26.
2
Trends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data.
Eur J Clin Pharmacol. 2023 Dec;79(12):1675-1685. doi: 10.1007/s00228-023-03572-7. Epub 2023 Oct 10.
3
Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop.
Stroke. 2023 Mar;54(3):e75-e85. doi: 10.1161/STROKEAHA.121.038273. Epub 2023 Feb 27.
4
Management of venous thromboembolism in morbidly obese patients: a 10-year review.
J Thromb Thrombolysis. 2023 Feb;55(2):304-311. doi: 10.1007/s11239-022-02738-x. Epub 2022 Dec 16.
5
Rivaroxaban Pharmacokinetics in Obese Subjects: A Systematic Review.
Clin Pharmacokinet. 2022 Dec;61(12):1677-1695. doi: 10.1007/s40262-022-01160-z. Epub 2022 Oct 6.
6
Physician perceptions and use of reduced-dose direct oral anticoagulants for extended phase venous thromboembolism treatment.
Res Pract Thromb Haemost. 2022 Jun 8;6(4):e12740. doi: 10.1002/rth2.12740. eCollection 2022 May.
7
Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry.
J Clin Med. 2021 Jun 29;10(13):2879. doi: 10.3390/jcm10132879.
8
Direct oral anticoagulant therapy in patients with morbid obesity after intermediate- or high-risk pulmonary emboli.
ERJ Open Res. 2021 Feb 1;7(1). doi: 10.1183/23120541.00554-2020. eCollection 2021 Jan.
9
Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity.
J Clin Med. 2021 Jan 8;10(2):200. doi: 10.3390/jcm10020200.
10
Venous thromboembolism research priorities: A scientific statement from the American Heart Association and the International Society on Thrombosis and Haemostasis.
Res Pract Thromb Haemost. 2020 Jul 8;4(5):714-721. doi: 10.1002/rth2.12373. eCollection 2020 Jul.
本文引用的文献
1
Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study.
Res Pract Thromb Haemost. 2018 Aug 29;2(4):684-688. doi: 10.1002/rth2.12146. eCollection 2018 Oct.
2
Monitoring of Apixaban in a Super Obese Patient.
Am J Med. 2019 Jan;132(1):e15-e16. doi: 10.1016/j.amjmed.2018.08.021. Epub 2018 Sep 7.
3
Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation.
Ann Pharmacother. 2019 Feb;53(2):165-170. doi: 10.1177/1060028018796604. Epub 2018 Aug 22.
4
The impact of body weight on rivaroxaban pharmacokinetics.
Res Pract Thromb Haemost. 2017 Oct 9;1(2):180-187. doi: 10.1002/rth2.12039. eCollection 2017 Oct.
5
Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations.
CPT Pharmacometrics Syst Pharmacol. 2018 May;7(5):309-320. doi: 10.1002/psp4.12288. Epub 2018 Apr 16.
6
Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119).
Int J Cardiol. 2018 Jul 1;262:85-91. doi: 10.1016/j.ijcard.2018.03.060. Epub 2018 Mar 14.
7
Trends in Obesity and Severe Obesity Prevalence in US Youth and Adults by Sex and Age, 2007-2008 to 2015-2016.
JAMA. 2018 Apr 24;319(16):1723-1725. doi: 10.1001/jama.2018.3060.
8
International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries.
Am Heart J. 2017 Dec;194:132-140. doi: 10.1016/j.ahj.2017.08.011. Epub 2017 Aug 24.
9
Effect of extremes of body weight on drug level in patient treated with standard dose of rivaroxaban for venous thromboembolism; real life experience.
Thromb Res. 2016 Nov;147:32-35. doi: 10.1016/j.thromres.2016.09.010. Epub 2016 Sep 14.
10
Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review.
Chest. 2017 Jan;151(1):127-138. doi: 10.1016/j.chest.2016.08.1462. Epub 2016 Sep 13.
Zotero 插件